Abstract
The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05%, which makes it more effective than female sterilization. It is discreet, easy to insert and remove, has no effect on future fertility and is associated with a number of noncontraceptive health benefits. The ENG implant is safe and effective when used in the postpartum and postabortion setting, and in women who have contraindications to estrogen. The most common reason cited for discontinuation is irregular and unpredictable bleeding. However, structured, preinsertion counseling can increase continuation and user satisfaction.
Financial & competing interests disclosure
JF Peipert receives research grant funding from Merck and Bayer, and served on an advisory board for Teva. C McNicholas and JF Peipert receive funding from the Washington University Institute of Clinical and Translational Sciences National Center for Research Resources grant UL1 RR024992 from the National Center for Advancing Translational Sciences, and C McNicholas receives support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH under award number T32HD055172. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.